Biotech Movers: Arena Gets Warned, MAP Gets an Offer

Among last week's highlights, Europe raises questions about Arena's obesity drug, Belviq, and Allergan offers $958 million for MAP Pharmaceuticals. More 

Dow Delivers Despite Iffy Earnings — Tuesday’s Market Recap

The Dow Jones powered ahead Tuesday despite some less-than-splendid earnings from Verizon and Johnson & Johnson. Also, Google impressed after hours. More 

Apple Keeps Biting the Nasdaq — Tuesday’s IP Market Recap

Apple stock finished below $500 for the first time in nearly a year, weighing down the Nasdaq on a day otherwise bolstered by hot retail stocks. More 

Stocks Dip on Pre-Earnings Jitters — Tuesday’s IP Market Recap

Investors leery of a potentially weak fourth-quarter earnings season bid stocks down lower Tuesday, though Alcoa "officially" started things off right after the bell. More 

4 Attractive Biopharma Stocks of All Sizes

Biopharma is a high-growth niche in a defensive sector, but you need to balance risk with reward. Here are four hot biopharma stocks of different sizes. More 

My Brilliant Biotech Move for 2012

An overly helter-skelter year in the world of biotech stocks has been a stark reminder of a basic lesson that isn't followed enough: Keep it simple. More 

Biotech Movers: Sequenom Soars on Blood Test Success

SONM sees significant gains despite a sub-par earnings report. Plus: Why Array and Vivus took big falls. More